Document:

Exhibit 10.1

Sport Endurance, Inc.

222 Broadway, 19th Floor

New York, NY 10038

April 18, 2017

Re: Sport Endurance, Inc. / Forbearance on Senior Secured Promissory Notes

Dear Sir:

This letter agreement (the “Agreement”) acknowledges that in exchange for Sport Endurance, Inc. (the “Company”), paying $_________ to ___________________ (the “Lender”), you agree that the due date under the 10% Senior Secured Promissory Note (the “Senior Note”) shall be extended to 5:00 pm Eastern Daylight Savings time on May 1, 2017 (the “Due Date”).

Without modifying or amending the terms of the Senior Note, the Security Agreement or the Purchase Agreement, the Lender agrees to forebear and not to seek collection against the Company of any amounts due under the Senior Note, Security Agreement or Purchase Agreement through and until the Due Date. The period of forbearance provided in this Agreement shall terminate on the Due Date if the amount due under the Senior Note is not paid within that period.

Except as modified by this Agreement, the Company hereby ratifies and confirms the terms and provisions of the Senior Note, the Security Agreement and the Purchase Agreement. The Senior Note, Security Agreement, Purchase Agreement and all other agreements, instruments and other documents executed in connection with the obligations of the Company under the Senior Note are legal, valid, binding and enforceable against the Company in accordance with their terms.

Any number of counterparts of this Agreement may be signed and delivered, each of which shall be considered an original and all of which, together, shall constitute one and the same instrument.

Please sign below evidencing your agreement to be bound by this Agreement and return to us.

Very truly yours,

_________________________

David Lelong

President and CEO

We hereby agree to the foregoing:

Lender

By:Exhibit 10.2

 

 

PROMISSORY NOTE

 

	
$56,000

	April 21, 2017

 

FOR VALUE RECEIVED, the undersigned (“Maker”) promises to pay to the order of David Lelong (the “Holder”) the sum of Fifty-Six Thousand Dollars ($56,000).  This Note shall bear interest at the rate of two percent (2%) per annum.  Said principal and interest is due and payable upon demand of the Holder.  Interest shall accrue on the sum of Forty-Five Thousand Dollars ($45,000) for the period of April 18, 2017 through April 20, 2017. Interest shall accrue on the sum of Fifty-Six Thousand Dollars ($56,000) for the period of April 21, 2017 through the date of repayment.

Payments shall be made of lawful money of the United States at such place designated in writing by the Holder at the time of demand.

All makers and endorsers now or hereafter becoming parties hereto jointly and severally waive demand, presentment, notice of non-payment in protest and, if this Note becomes in default and is placed into the hands of an attorney for collection, to pay attorneys’ fees and all other costs for making such collection, provided the Holder is the prevailing party.

This Note may not be changed or terminated orally, but only with an agreement in writing, signed by the parties against whom enforcement of any waiver, change, modification or discharge is sought, with such agreement being effective and binding only upon the parties thereto.

Each of the Maker and the Holder hereby waives any right to a trial by jury in any action or proceeding to enforce or defend any rights under this note and any amendment, instrument, document or agreement delivered or which may in the future be delivered in connection herewith or therewith or arising from any relationship existing in connection with any of the foregoing, and agrees that any such action or proceeding shall be tried before a court and not before a jury.

This Note and the rights and obligations of the Holder and of the undersigned shall be governed by and construed and enforced in accordance with the laws of the State of New York.

 

SPORT ENDURANCE, INC.

By:  /s/ David Lelong                                               

      David Lelong

      Chief Executive OfficerSECURITIES
PURCHASE AGREEMENT

 

 

THIS
PURCHASE AGREEMENT (“Agreement”) is made as of the 18th day of April, 2017 by and between Rich Pharmaceuticals,
Inc., (the “Company”), and GHS Investments, LLC (the “Investor”).

 

Recitals

 

A.       The
Investor wishes to purchase from the Company and the Company wishes to sell and issue to the Investor,
upon the terms and conditions stated in this Agreement:

 

1.
Up to $115,000 of Securities, in the form of a Convertible Promissory Note (the "Note"),
attached hereto in accordance with the following schedule:

 

Twenty
Five thousand dollars ($25,000) by wire transfer
upon the Closing (as defined below) and three (3) subsequent weekly tranches of twenty five thousand dollars ($25,000) at the
discretion of the Investor (“Subsequent Tranches”).

 

In
consideration of the mutual promises made herein and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties hereto agree as follows:

 

1.                 
Definitions. In addition to those terms defined above and elsewhere in this Agreement, for the purposes of this Agreement,
the following terms shall have the meanings set forth below:

 

“Affiliate”
means, with respect to any Person, any other
Person which directly or indirectly through one or more intermediaries Controls, is controlled by,
or is under common control with, such Person.

 

“Business
Day” means a day, other than
a Saturday or Sunday, on which banks in New York
City are open for the general transaction of business.

 

“Common
Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
acquire at any time Common Stock, including without limitation, any debt, preferred stock, rights, options, warrants or other
instrument that is at any time convertible into or exchangeable for, or otherwise
entitles the holder thereof to receive, Common Stock.

    	 

    	 

    

“Company’s
Knowledge”
means the actual knowledge of the executive officers (as defined in Rule 405 under
the 1933 Act) of the Company, after due inquiry.

 

“Confidential
Information” means trade secrets, confidential information and know-how (including but not limited to ideas, formulae,
compositions, processes, procedures and techniques, research and development information, computer program code, performance specifications,
support documentation, drawings, specifications, designs, business and marketing plans, and customer and supplier lists and related
information).

 

“Control”
(including the terms “controlling”, “controlled by” or “under common control with”) means
the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person,
whether through the ownership of voting securities, by contract or otherwise.

 

“Intellectual
Property” means all of the following: (i) patents, patent applications, patent disclosures and inventions (whether or
not patentable and whether or not reduced to practice); (ii) trademarks, service marks, trade dress, trade names, corporate names,
logos, slogans and Internet domain names, together with all goodwill associated with each of the foregoing; (iii) copyrights and
copyrightable works; (iv) registrations, applications and renewals for any of the foregoing; and (v) proprietary computer software
(including but not limited to data, data bases and documentation).

 

“Material
Adverse Effect” means a material
adverse effect on (i) the assets, liabilities, results of operations, condition (financial
or otherwise), business, or prospects of the Company and its Subsidiaries taken as a whole, or (ii) the ability of the Company
to perform its obligations under the Transaction Documents.

 

“Person”
means an individual, corporation, partnership, limited liability company, trust, business
trust, association, joint stock company, joint venture, sole proprietorship, unincorporated
organization, governmental authority or any other form of entity not specifically
listed herein.

 

“Purchase
Price”
means $100,000, representing a 10% original issuance discount on the Note and an
initial $5,000 to offset transaction costs.

 

“SEC”
means the United States Securities and Exchange
Commission.

 

“Securities”
means the Note and the common shares issuable at conversion.

 

“Subsidiary”
of any Person means another Person, an amount of the voting securities, other voting ownership or voting partnership interests
of which is sufficient to elect at least a majority of its Board of Directors or
other governing body (or, if there are no such voting interests, 50% or more of the
equity interests of which) is owned directly or indirectly by such first Person.

    	 	1	 

    	 	 	 

    

 

“Transaction
Documents”
means this Agreement, the Note, the Company Representation Letter, and supporting
documents.

 

“1933
Act” means the Securities Act of 1933, as amended, or any successor statute, and the rules and regulations promulgated
thereunder.

 

“1934
Act” means the Securities Exchange Act of 1934, as amended, or any successor statute, and the rules and regulations
promulgated thereunder.

 

2.              Purchase
and Sale of the Securities. Subject to the terms and conditions of this Agreement, the Company shall sell and issue to the
Investor a Promissory Note in the principal amount of $115,000.00

 

2.1            Security
As Security for the Company's obligations contained herein and in all Notes issued
by the Company to the Holder,
following any Event of Default which remains uncured for thirty (30) calendar
days, the Holder shall be granted an unconditional first priority interest in and
to, any and all property of the Company and its subsidiaries, of any kind or description,
tangible or intangible, whether now existing or hereafter arising or acquired
until the balance of all Notes has been reduced to $0. "Any and all property,"
as described herein shall be inclusive of, but not limited to, assets reported
by the Company on its SEC filings, cash, inventory, accounts receivable,
intellectual property rights, equipment and property.
The Investor is authorized to make all filings the Investor, in its discretion,
deems necessary to evidence its security interests.

 

3.             Closing.
Upon confirmation that the other conditions to closing specified herein have been satisfied or duly waived by the Investor,
the Company shall deliver to the Investor, a Note registered the name of the
Investor and the Investor shall cause a wire transfer in same day funds to be sent to the account of the Company as instructed
in writing by the Company, in an amount representing the Purchase Price for the Note
(the “Closing Date”).

 

4.             Representations
and Warranties of the Company.
The Company hereby represents and warrants to the Investor that, except as set forth in the schedules delivered herewith
(collectively, the “Disclosure Schedules”) and as disclosed in the Company’s
SEC Filings:

 

4. 
1 Organization, Good Standing and Qualification. Each of the Company
and its Subsidiaries is a corporation duly organized, validly existing and in good
standing under the laws of the jurisdiction of its incorporation and has all requisite corporate power and authority to carry
on its business as now conducted and to own its properties. Each of the Company and its Subsidiaries is duly qualified to do business
as a foreign corporation and is in

    	 

    	 

    

good
standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property makes such qualification
or leasing necessary unless the failure to so qualify has not and could not reasonably be expected to have a Material Adverse
Effect. The Company’s Subsidiaries
are listed on the Company’s public disclosures filed with the SEC.

 

4.2             
Authorization. The Company has full power and authority and, has taken all requisite action on the part of the Company,
its officers, directors and stockholders necessary for (i) the authorization,
execution and delivery of the Transaction Documents, (ii) authorization of the performance
of all obligations of the Company hereunder or thereunder, and (iii) the authorization,
issuance (or reservation for issuance) and delivery of the Securities. The Transaction
Documents constitute the legal, valid and binding obligations of the Company, enforceable
against the Company in accordance with their terms, subject to bankruptcy, insolvency,
fraudulent transfer, reorganization, moratorium
and similar laws of general applicability, relating to or affecting
creditors’ rights generally.

 

4.3             
Capitalization. As of the date hereof, the authorized common stock of the Company on the date hereof is 4,000,000,000;
(b) the number of shares of capital stock issued and outstanding as of December 13, 2016 is 1,307,401,310; (c) the number of shares
of capital stock issuable pursuant to the Company’s stock plans is11,999,978;
and (d) the number of shares of capital stock issuable and reserved for issuance pursuant to securities (other than the
Securities) exercisable for, or convertible into or exchangeable for any shares of
capital stock of the Company as of December 13, 2016 are2,680,624,251. All of the issued and outstanding shares of the Company’s
capital stock have been duly authorized and validly issued and are fully paid, nonassessable and free of pre-emptive rights.
All of the issued and outstanding shares of capital stock of each Subsidiary have been duly authorized and validly issued and
are fully paid, nonassessable and free of pre-emptive rights, were issued in full compliance with applicable state and federal
securities law and any rights of third parties and are owned by the Company, beneficially
and of record, subject to no lien, encumbrance or other adverse claim. No Person is entitled to pre-emptive or similar statutory
or contractual rights with respect to any securities of the Company. Other than described
herein and in the Company's periodic reports filed with the SEC, there are no outstanding warrants, options, convertible securities
or other rights, agreements or arrangements of any character under which the Company or any of its Subsidiaries is or may be obligated
to issue any equity securities of any kind and except as contemplated by this Agreement, neither the Company nor any of its Subsidiaries
is currently in negotiations for the issuance of any equity securities of any kind.

 

The
issuance and sale of the Securities hereunder will not obligate the Company to issue shares of Common Stock or other securities
to any other Person (other than the Investor) and will not result in the adjustment of the exercise, conversion, exchange or reset
price of any outstanding security.

    	 

    	 

    

The
Company does not have outstanding stockholder purchase rights or “poison pill” or any similar arrangement in effect
giving any Person the right to purchase any equity interest in the Company upon the occurrence of certain events.

 

4.4             
Valid Issuance. The issued Securities have been duly and validly authorized
and, when issued and paid for pursuant to this Agreement, shall be free and clear of all encumbrances and restrictions (other
than those created by the Investor), except for restrictions on transfer set forth in the Transaction
Documents or imposed by applicable securities laws. Upon the due conversion of the Debenture, the Converted Shares will
be validly issued, fully paid and non-assessable free and clear of all encumbrances and restrictions, except for restrictions
on transfer set forth in the Transaction Documents or imposed by applicable securities
laws and except for those created by the Investor. The Company has reserved a sufficient
number of shares of Common Stock for issuance upon the exercise of the Debenture, free and clear of all encumbrances and
restrictions, except for restrictions on transfer set forth in the Transaction Documents
or imposed by applicable securities laws and except for those created by the Investor.

 

4.5             
Consents. The execution, delivery and performance by the Company of the Transaction
Documents, and the offer, issuance and sale of the Securities require no consent
of, action by or in respect of, or filing with, any Person, governmental body, agency,
or official other than filings that have been made pursuant to applicable
state securities laws, and post-sale filings pursuant to applicable state and federal securities laws which the Company undertakes
to file within the applicable time periods. Subject to the accuracy of the representations and warranties of the Investor set
forth in Section 5 hereof, the Company has taken all action necessary to exempt (i) the issuance and sale of the Securities, (ii)
the issuance of the Shares upon due conversion of the Debenture, and (iii) the other transactions contemplated by the Transaction
Documents from the provisions of any shareholder rights plan or other “poison pill” arrangement, any anti-takeover,
business combination or control share law or statute binding on the Company or to which the Company or any of its assets
and properties may be subject and any provision of the Company’s Articles of Incorporation or By-laws that is or could reasonably
be expected to become applicable to the Investor as a result of the transactions contemplated hereby,
including without limitation, the issuance of the Securities and the ownership, disposition or voting of the Securities
by the Investor or the exercise of any right granted to the Investor pursuant to this Agreement or the other Transaction
Documents.

 

4.6             
Delivery of SEC Filings; Business. The Company has made available to the Investor through the EDGAR system, true and complete
copies of the Company’s most recent Annual Report on Form 10-K for its last
fiscal year (the “10-K”), and all other reports filed by the Company pursuant to the 1934 Act since the filing of
the 10-K and prior to the date hereof (collectively, the “SEC Filings”).
The SEC Filings are the only filings required of the Company pursuant to the 1934 Act for such period. The Company and its Subsidiaries
are engaged in all material respects only in the business described in the SEC Filings and the SEC Filings contain a complete
and accurate description in all material respects of the business of the Company and its Subsidiaries, taken as a whole.

    	 	2	 

    	 	 	 

    

 

4.7             
Use of Proceeds. The net proceeds of the sale of the Note hereunder shall be used by the Company for working capital and
general corporate purposes. The Company agrees that it shall not use the funds from this Agreement, at any time, to lend money,
give credit or make advances to any officers, directors, employees, subsidiaries
and affiliates of the Company.

 

4.8             
No Conflict, Breach, Violation or Default. The execution, delivery and performance
of the Transaction Documents by the Company and the issuance and sale of the Securities
will not conflict with or result in a breach or violation of any of the terms and provisions of, or constitute a default under
(i) the Company’s Articles of Incorporation or the Company’s
Bylaws, both as in effect on the date hereof (true and complete copies of
which have been made available to the Investor through the EDGAR system), or (ii)(a) any statute, rule, regulation or order of
any governmental agency or body or any court, domestic or foreign, having jurisdiction over the Company,
any Subsidiary or any of their respective assets or properties, or (b) any agreement or instrument to which the Company
or any Subsidiary is a party or by which the Company or a Subsidiary is bound or to which any of their respective assets or properties
is subject.

 

4.9             
Brokers and Finders. No Person will have, as a result of the transactions contemplated by the Transaction
Documents, any valid right, interest or claim against or upon the Company,
any Subsidiary or an Investor for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding
entered into by or on behalf of the Company.

 

4.10         
No Directed Selling Efforts or General Solicitation. Neither the Company nor
any Person acting on its behalf has conducted any general solicitation or general advertising (as those terms are used in Regulation
D) in connection with the offer or sale of any of the Securities.

 

4.11         
No Integrated Offering. Neither
the Company nor any of its Affiliates, nor any Person acting on its or their behalf
has, directly or indirectly, made any offers
or sales of any Company security or solicited any offers to buy any security,
under circumstances that would adversely affect reliance by the Company on
Section 4(2) for the exemption from registration for the transactions contemplated hereby or would require registration of the
Securities under the 1933 Act.

 

4.12         
Private Placement. The offer and sale of the Securities to the Investor as
contemplated hereby is exempt from the registration requirements of the 1933 Act.

    	 

    	 

    

5.                 
Representations and Warranties of the Investor.
The Investor hereby represents and warrants to the Company that:

 

5.1             
Organization and Existence. Such Investor is a validly existing corporation,
limited partnership or limited liability company and has all requisite corporate, partnership or limited liability company power
and authority to invest in the Securities pursuant to this Agreement.

 

5.2             
Authorization. The execution, delivery and performance by such Investor of the Transaction
Documents to which such Investor is a party have been duly authorized and will each constitute the valid and legally binding
obligation of such Investor, enforceable against such Investor in accordance with
their respective terms, subject to bankruptcy, insolvency, fraudulent transfer,
reorganization, moratorium and similar laws of general applicability,
relating to or affecting creditors’ rights generally.

 

5.3             
Purchase Entirely for Own Account. The Securities to be received by such Investor hereunder will be acquired for such Investor’s
own account, not as nominee or agent, and not with a view to the resale or distribution of any part thereof in violation
of the 1933 Act, and such Investor has no present intention of selling, granting any participation in, or otherwise distributing
the same in violation of the 1933 Act without prejudice, however, to such Investor’s
right at all times to sell or otherwise dispose of all or any part of such Securities in compliance with applicable federal
and state securities laws. Nothing contained herein shall be deemed a representation or warranty by such Investor to hold
the Securities for any period of time. Such Investor is not a broker-dealer registered
with the SEC under the 1934 Act or an entity engaged in a business that would require it to be so registered.

 

5.4             
Investment Experience. Such Investor acknowledges that it can bear the economic risk and complete loss of its investment
in the Securities and has such knowledge and experience in financial or business matters that it is capable of evaluating the
merits and risks of the investment contemplated hereby.

 

5.5             
Disclosure of Information. Such Investor has had an opportunity to receive all information related to the Company requested
by it and to ask questions of and receive answers from the Company regarding the Company,
its business and the terms and conditions of the offering of the Securities.
Such Investor acknowledges receipt of copies of the SEC Filings. Neither such inquiries nor any other due diligence investigation
conducted by such Investor shall modify, amend or affect such Investor’s
right to rely on the Company’s representations and warranties contained
in this Agreement.

 

5.6             
Restricted Securities. Such Investor understands that the Securities are characterized as “restricted securities”
under the U.S. federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public
offering and that under such laws and applicable regulations such securities may
be resold without registration under the 1933 Act only in certain limited circumstances.

    	 	3	 

    	 	 	 

    

 

5.7             
Legends. It is understood that, except as provided below, certificates evidencing
the Securities may bear the following or any similar legend:

 

(a)              
“The securities represented hereby may not be transferred unless (i) such securities have been registered for sale pursuant
to the Securities Act of 1933, as amended, (ii) such securities may be sold pursuant to Rule 144(i), or (iii) the Company has
received an opinion of counsel reasonably satisfactory to it that such transfer may lawfully be made without registration under
the Securities Act of 1933 or qualification under applicable state securities laws.”

 

(b)              
If required by the authorities of any state in connection with the issuance of sale of the Securities, the legend required by
such state authority.

 

5.8             
Accredited Investor. Such Investor
is an accredited investor as defined in Rule 501(a) of Regulation D, as amended, under the 1933 Act.

 

5.9             
No General Solicitation. Such Investor did not learn of the investment in the Securities as a result of any public advertising
or general solicitation.

 

5.10         
Brokers and Finders. No Person will have, as a result of the transactions contemplated by the Transaction
Documents, any valid right, interest or claim against or upon the Company,
any Subsidiary or an Investor for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding
entered into by or on behalf of such Investor.

 

		6.	Conditions
                                         to Closing.

 

6.1             
Conditions to the Investor’s Obligations. The obligation of the Investor
to purchase the Note at Closing is subject to the fulfillment to such Investor’s satisfaction,
on or prior to the Closing Date, of the following conditions, any of which may be waived by the Investor:

 

(a)              
The representations and warranties made by the Company in Section 4 hereof qualified as to materiality shall be true and correct
at all times prior to and on the Closing Date, except to the extent any such representation or warranty expressly speaks as of
an earlier date, in which case such representation or warranty shall be true and correct as of such earlier date, and, the representations
and warranties made by the Company in Section 4 hereof not qualified as to materiality shall be true and correct in all material
respects at all times prior to and on the Closing Date, except to the extent any such representation or warranty expressly speaks
as of an earlier date, in which case such representation or warranty shall be true and correct in all material respects as of
such earlier date. The Company shall have performed in all material respects all obligations and conditions herein required to
be performed or observed by it on or prior to the Closing Date.

    	 	4	 

    	 	 	 

    

 

(b)              
The Company shall have obtained any and all consents, permits, approvals, registrations and waivers necessary or appropriate for
consummation of the purchase and sale of the Securities, and the consummation of the other transactions contemplated by the Transaction
Documents, all of which shall be in full force and effect.

 

(c)              
No judgment, writ, order, injunction, award or decree of or by any court, or judge,
justice or magistrate, including any bankruptcy court or judge, or any order of or by any governmental authority,
shall have been issued, and no action or proceeding shall have been instituted by any governmental authority,
enjoining or preventing the consummation of the transactions contemplated hereby or in the other Transaction
Documents.

 

(d)              
The Company shall have executed and delivered the Convertible Note and supporting documentation.

 

(e)              
The Company shall have executed and delivered the Irrevocable Transfer Agent Instructions.

 

(f)               
No stop order or suspension of trading shall have been imposed by the public markets on which the Company’s
common stock is traded or quoted, the SEC or any other governmental or regulatory body with respect to public trading in
the Common Stock.

 

6.2             
Conditions to Obligations of the Company.
The Company's obligation to sell and issue the Note at Closing is subject to the fulfillment to the satisfaction of the
Company on or prior to the Closing Date of the following conditions, any of which may be waived by the Company:

 

(a)              
The representations and warranties made by the Investor in Section 5 hereof, other than the representations and warranties contained
in Sections 5.3, 5.4, 5.5, 5.6, 5.7, 5.8 and 5.9 (the “Investment Representations”), shall be true and correct in
all material respects when made, and shall be true and correct in all material respects on the Closing Date with the same force
and effect as if they had been made on and as of said date. The Investment Representations
shall be true and correct in all respects when made, and shall be true and correct in all respects on the Closing Date with the
same force and effect as if they had been made on and as of said date. The Investor
shall have performed in all material respects all obligations and conditions herein required to be performed or observed by them
on or prior to the Closing Date.

 

(b)              
The Investor shall have delivered the Purchase Price to the Company in accordance with the schedule outlined herein.

    	 

    	 

    

 

		6.3	Termination
                                         of
                                         Obligations to Effect Closing; Effects.

 

(a)              
The obligations of the Company, on the one hand, and the Investor,
on the other hand, to effect the Closing shall terminate as follows:

(i)          Upon
the mutual written consent of the Company and the Investor;

 

(ii)            By
the Company if any of the conditions set forth in Section 6.2 shall have become incapable of fulfillment, and shall not have been
waived by the Company;

 

		(iii)	By
                                         the Investor if any of the conditions set forth in Section

6.1
shall have become incapable of fulfillment, and shall not have been waived by the Investor; orprovided, however,
that, except in the case of clause (i) above, the party seeking to terminate its obligation to effect
the Closing shall not then be in breach of any of its representations, warranties, covenants or agreements contained in
this Agreement or the other Transaction Documents if such breach has resulted in
the circumstances giving rise to such party’s seeking to terminate its obligation
to effect the Closing.

 

		7.	Survival
                                         and Indemnification.

 

7.1     
Survival. The representations, warranties, covenants and agreements contained in this Agreement shall survive the Closing
of the transactions contemplated by this Agreement.

 

7.2  
Indemnification. The Company agrees to indemnify and hold harmless each Investor and its Affiliates
and their respective directors, officers, employees and agents from and against
any and all losses, claims, damages, liabilities and expenses (including without limitation reasonable attorney fees and disbursements
and other expenses incurred in connection with investigating, preparing or defending any action, claim or proceeding, pending
or threatened and the costs of enforcement thereof) (collectively, “Losses”)
to which such Person may become subject as a result of any breach of representation, warranty,
covenant or agreement made by or to be performed on the part of the Company under the Transaction
Documents, and will reimburse any such Person for all such amounts as they are incurred by such Person.

 

7.3
Conduct of Indemnification Proceedings. Promptly after receipt by any Person (the “Indemnified
Person”) of notice of any demand, claim or circumstances which would or might give rise to a claim or the commencement of
any action, proceeding or investigation in respect of which indemnity may be sought pursuant to Section 7.2, such Indemnified
Person shall promptly notify the Company in writing and the Company shall assume the defense thereof, including the employment
of counsel reasonably satisfactory to such

    	 

    	 

    

Indemnified
Person, and shall assume the payment of all fees and expenses; provided, however,that
the failure of any Indemnified Person so to notify the Company shall not relieve the Company of its obligations hereunder
except to the extent that the Company is materially prejudiced by such failure to notify.
In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses
of such counsel shall be at the expense of such Indemnified Person unless: (i) the Company and the Indemnified Person shall have
mutually agreed to the retention of such counsel; or (ii) in the reasonable judgment of counsel to such Indemnified Person representation
of both parties by the same counsel would be inappropriate due to actual or potential differing
interests between them. The Company shall not be liable for any settlement of any proceeding effected
without its written consent, which consent shall not be unreasonably withheld, but if settled with such consent, or if
there be a final judgment for the plaintiff, the Company shall indemnify and hold
harmless such Indemnified Person from and against any loss or liability (to the extent stated above) by reason of such settlement
or judgment. Without the prior written consent of the Indemnified Person, which consent
shall not be unreasonably withheld, the Company shall not affect any settlement of
any pending or threatened proceeding in respect of which any Indemnified Person is or could have been a party and indemnity could
have been sought hereunder by such Indemnified Party, unless such settlement includes
an unconditional release of such Indemnified Person from all liability arising out of such proceeding.

 

		8.	Miscellaneous.

 

8.1             
Successors and Assigns. This
Agreement may not be assigned by a party hereto without the prior written consent of the Company or the Investor,
as applicable, provided, however, that an Investor may assign its rights and
delegate its duties hereunder in whole or in part to an Affiliate or to a third party
acquiring some or all of its Securities in a private transaction without the prior written consent of the Company,
after notice duly given by such Investor to the Company. The provisions of
this Agreement shall inure to the benefit of and be binding upon the respective permitted successors and assigns of the parties.
Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective
successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly
provided in this Agreement.

 

8.2             
Counterparts; This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument. This Agreement may also be executed via facsimile, which shall
be deemed an original.

 

8.3             
Titles and Subtitles. The titles and subtitles used in this Agreement
are used for convenience only and are not to be considered in construing or interpreting this Agreement.

    	 

    	 

    

8.4             
Notices. Unless otherwise provided, any notice required or permitted under this Agreement shall be given in writing and
shall be deemed effectively given as hereinafter described (i) if given by personal
delivery, then such notice shall be deemed given upon such delivery,
(ii) if given by fax, then such notice shall be deemed given upon receipt of confirmation of complete transmittal, (iii)
if given by mail, then such notice shall be deemed given upon the earlier of (A) receipt of such notice by the recipient or (B)
three days after such notice is deposited in first class mail, postage prepaid, and (iv) if given by an internationally recognized
overnight air courier, then such notice shall be deemed given one business day after
delivery to such carrier. All notices shall be addressed to the party to be notified
at the address as follows, or at such other address as such party may designate by ten days’ advance written notice to the
other party:

 

If
to the Company:

 

Rich
Pharmaceuticals, Inc. 

9595
Wilshire Blvd., Suite 900, Beverly Hills, CA 90212

Attn:
Ben Chang 

 

Fax:
424-230-7003 

Tel:
424-230-7001 

 

If
to the Investor:

 

GHS
Investments, LLC

420
Jericho Turnpike, Suite 207

Jericho,
NY 11753

 

8.5             
Expenses. The parties hereto shall pay their own costs and expenses in connection herewith. In the event that legal proceedings
are commenced by any party to this Agreement against another party to this Agreement in connection with this Agreement or the
other Transaction Documents, the party or parties which do not prevail in such proceedings
shall severally, but not jointly, pay
their pro rata share of the reasonable attorneys’ fees and other reasonable out-of-pocket costs and expenses incurred by
the prevailing party in such proceedings.

 

8.6             
Amendments and Waivers. Any term
of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular
instance and either retroactively or prospectively), only with the written consent of the Company and the Investor.
Any amendment or waiver effected in accordance with this paragraph shall be binding upon each holder of any Securities
purchased under this Agreement at the time outstanding, each future holder of all such Securities, and the Company.

    	 	5	 

    	 	 	 

    

 

8.7             
Severability. Any provision of this Agreement that is prohibited or unenforceable
in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent
of such prohibition or unenforceability without invalidating the remaining provisions hereof but shall be interpreted as if it
were written so as to be enforceable to the maximum extent permitted by applicable law,
and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in
any other jurisdiction. To the extent permitted by applicable law, the parties hereby
waive any provision of law which renders any provision hereof prohibited or unenforceable in any respect.

 

8.8             
Entire Agreement. This Agreement, including the Exhibits and the Disclosure Schedules, and the other Transaction
Documents constitute the entire agreement among the parties hereof with respect to the subject matter hereof and thereof
and supersede all prior agreements and understandings, both oral and written, between the parties with respect to the subject
matter hereof and thereof.

 

8.9             
Further Assurances. The parties shall execute and deliver all such further instruments and documents and take all such
other actions as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment
of the agreements herein contained.

 

8.10         
Governing Law; Consent to Jurisdiction; Waiver
of Jury Trial. This Agreement
shall be governed by, and construed in accordance with, the internal laws of the State
of Nevada, without regard to principles of conflicts of law.
Each of the parties hereto irrevocably submit to the exclusive jurisdiction of the state and federal courta sitting in
New York City,
New York over any action or proceeding arising out of or relating to this Agreement
and the parties hereto hereby irrevocably agree that all claims in respect of such action or proceeding may be heard and determined
in such court. The parties hereto agree that a final judgment in any such action or proceeding shall be conclusive and may be
enforced in other jurisdictions by suit on the judgment or in any other manner provided by law.
The parties hereto further waive any objection to venue in the State of New York
and any objection to an action or proceeding in the State of New York on the basis
of forum non conveniens.

 

[signature
page follows]

    	 

    	 

    

IN
WITNESS WHEREOF, the parties have executed this Agreement or caused their duly authorized
officers to execute this Agreement as of the date first above written.

 

The
Company:Rich Pharmaceuticals, Inc.

 

 

 By:
/s/ Ben Chang

Name:
Ben Chang 

Title:
CEO

 

The
Investor:GHS Investments, LLC.

 

By:
/s/ Member

Member

    	 	6	 

    	 	 	 

    

  

Disclosure
Schedules/ Exhibits

    	 	7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}]]